Annexon Biosciences, Inc. (ANNX) has disclosed a new risk, in the Capital Markets category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Annexon Biosciences, Inc. faces significant risks due to its reliance on international third-party suppliers in a volatile global trade environment. The company’s dependence on foreign manufacturing for its product candidates, tanruprubart and vonaprument, exposes it to potential disruptions from tariffs, sanctions, and trade barriers. These factors could lead to increased research and development costs, supply chain complexities, and delays in development timelines, ultimately affecting its financial condition and growth prospects. The uncertainty surrounding international trade policies necessitates vigilant risk management to mitigate potential adverse impacts on its operations.
The average ANNX stock price target is $11.00, implying 350.82% upside potential.
To learn more about Annexon Biosciences, Inc.’s risk factors, click here.